So why is it that in 2009, according to IMS data, 33 compounds were expected to be blockbusters but only 10 actually came through? Or that something like Exubera, the inhaled insulin that seemed like a slam dunk, could be withdrawn from the market for poor sales less than two years after launch?
I offer up that a main problem is one of alignment. Or, more accurately, the lack thereof.As you enter the launch process, your plans start intact. Your goals, objectives, strategies, and tactics are all neatly aligned. Each part interlocks, creating a tight fit that completes a picture and neatly supports each other. But after running the promotional gauntlet, where it seems everyone from senior management, to the global marketing group, to the FDA is determined to trip you up on your way to launch, your marketing program feels like it's suddenly hit a pothole and won't drive straight. ("Running the gauntlet" is a practice that's been used for centuries as a rite of passage or form of punishment. Lucky participants were asked to run between two rows—the gauntlet—of armed opponents ready to strike from either side. If they survived, they were allowed to live. Sound familiar?)
What Needs Alignment?
Before we talk about how to avoid hitting potholes, let's talk about what needs alignment in the first place:
1) Your product with their need. This really should go without saying, but I can't tell you how many products we've worked on that are fresh out of R&D or Phase III trials yet lack a clear, compelling reason for being. Meeting a prescriber or patient need doesn't mean announcing a miracle cure—but it does mean solving a problem, offering a better alternative to current practice, or at least one-upping the other guy.
2) Marketing's expectations with medical's data. Clinical data form the marketing platform (especially at launch) for most pharma brands. It drives labeling, positioning, claims, and promotion. And physicians can always see through an ad hoc analysis, no matter how good the bar graph looks. The bottom line is you've got to align your vision for the brand with the clinical development plan or you'll miss your mark.
3) Tactics with strategy. The product manager down the hall ran a successful tablet tool sales aid program, your boss is intrigued by your competition's Facebook promotion, and on your last brand you were a hero with an e-mail sampling offer. Stop right there and think: Is there a strategy buried in there, or is this just the digital tactic of the week?
4) Sales forecasts with sales incenties. What gets incentivized gets detailed. So before you pour everything you've got into a great campaign of rep materials, make sure they're getting paid. Don't treat a third-position product like a first-position one, or that great campaign will just end up in a reps' trunk.
5) Marketing with sales with med/reg with manufacturing, and so on. If you're going to succeed over the course of a one-, two-, or three-year plan, you'd better rally the troops well before you start the long march. Give them a clear idea of what you're trying to accomplish, and they may actually put down some of those slings and arrows.
Sounds reasonable enough, yes? Like many things in marketing, alignment comes down to having clear objectives, a clear strategy, and good communication and relationships among your team.
But there's still the gauntlet. So what do you do when sales management wants to try a new incentive plan that takes your product out of the top tier, knocking your detail plan out of whack? Or when manufacturing says the stability data from the trial production batches are unclear and they'll need another six months of testing, ensuring the launch will now happen after the year's biggest congress opportunity? Or when your boss wants you to add a series of digital promotions because he was just at a seminar and has seen the light, sending you scrambling for additional budget? Or, my personal favorite, when senior management raises your forecast and lowers your budget because they believe you are underestimating your brand's potential and are sandbagging the numbers, forcing you into an aggressive launch mode with a slow build plan?